Follow
Mayank Ajmera
Mayank Ajmera
Lead, HEOR, Astellas Pharmaceuticals
Verified email at astellas.com
Title
Cited by
Cited by
Year
Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica
MR Ajmera, A Boscoe, J Mauskopf, SD Candrilli, M Levy
Journal of the neurological sciences 384, 96-103, 2018
1022018
Prescription drug use and polypharmacy among Medicaid-enrolled adults with autism: A retrospective cross-sectional analysis
R Vohra, S Madhavan, U Sambamoorthi, C StPeter, S Poe, N Dwibedi, ...
Drugs-real world outcomes 3, 409-425, 2016
402016
A real‐world study of the effect of timing of insulin initiation on outcomes in older Medicare beneficiaries with type 2 diabetes mellitus
R Bhattacharya, S Zhou, W Wei, M Ajmera, U Sambamoorthi
Journal of the American Geriatrics Society 63 (5), 893-901, 2015
332015
Perception of cancer recurrence risk: more information is better
KM Kelly, M Ajmera, S Bhattacharjee, R Vohra, G Hobbs, L Chaudhary, ...
Patient education and counseling 90 (3), 361-366, 2013
332013
Dual Medicare and Veteran Health Administration use and ambulatory care sensitive hospitalizations
M Ajmera, TL Wilkins, U Sambamoorthi
Journal of general internal medicine 26, 669-675, 2011
312011
Explaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive pulmonary …
M Ajmera, AD Raval, C Shen, U Sambamoorthi
International journal of chronic obstructive pulmonary disease, 339-348, 2014
302014
Multimorbidity, mental illness, and quality of care: preventable hospitalizations among medicare beneficiaries
M Ajmera, TL Wilkins, PA Findley, U Sambamoorthi
International Journal of Family Medicine 2012, 2012
282012
Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults
R Bhattacharya, M Ajmera, S Bhattacharjee, U Sambamoorthi
Diabetes research and clinical practice 105 (2), 251-260, 2014
242014
A real-world observational study of time to treatment intensification among elderly patients with inadequately controlled type 2 diabetes mellitus
M Ajmera, A Raval, S Zhou, W Wei, R Bhattacharya, C Pan, ...
Journal of managed care & specialty pharmacy 21 (12), 1184, 2015
232015
Treatment intensification in type 2 diabetes: a real-world study of 2-OAD regimens, GLP-1 RAs, or basal insulin
L Blonde, D Raccah, E Lew, J Meyers, E Nikonova, M Ajmera, KL Davis, ...
Diabetes Therapy 9, 1169-1184, 2018
202018
Multimorbidity and COPD medication receipt among Medicaid beneficiaries with newly diagnosed COPD
M Ajmera, U Sambamoorthi, A Metzger, N Dwibedi, G Rust, C Tworek
Respiratory care 60 (11), 1592-1602, 2015
202015
Association between statin medications and COPD-specific outcomes: a real-world observational study
M Ajmera, C Shen, U Sambamoorthi
Drugs-real world outcomes 4, 9-19, 2017
142017
Concomitant medication use and new-onset diabetes among medicaid beneficiaries with chronic obstructive pulmonary disease
M Ajmera, C Shen, U Sambamoorthi
Population Health Management 20 (3), 224-232, 2017
122017
An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States
CF Bell, MR Ajmera, J Meyers
Lupus 31 (2), 202-211, 2022
112022
A real-world analysis of relapses and costs of neuromyelitis optica spectrum disorders using a United States administrative claims database (P6. 161)
D Stafkey-Mailey, A Boscoe, M Ajmera, J Mauskopf, U Iloeje, M Levy
Neurology 86 (16_supplement), P6. 161, 2016
92016
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review
F Passamonti, FH Heidel, RC Parikh, M Ajmera, D Tang, JA Nadal, ...
Future Oncology 18 (18), 2217-2231, 2022
82022
Use of antifungals and outcomes among inpatients at risk of invasive Aspergillosis or Mucormycosis in the USA: a retrospective cohort study
K Stull, E Esterberg, M Ajmera, S Candrilli, TM Kitt, JR Spalding, VP Patel
Infectious Diseases and Therapy 8, 641-655, 2019
82019
What’s been the bang for the buck? Cost-effectiveness of health care spending across selected conditions in the US
D Wamble, M Ciarametaro, K Houghton, M Ajmera, RW Dubois
Health Affairs 38 (1), 68-75, 2019
82019
Impact of antiepileptic-drug treatment burden on health-care-resource utilization and costs
K Rajagopalan, SD Candrilli, M Ajmera
ClinicoEconomics and Outcomes Research, 619-627, 2018
82018
Quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib in real-world …
G Rocque, JL Blum, A Montero, I Nakhoul, S Kurian, RC Frank, B Telivala, ...
2019 San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, 2019
72019
The system can't perform the operation now. Try again later.
Articles 1–20